Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Recruiting2
Enrolling By Invitation1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06723106Phase 1Enrolling By Invitation

Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

NCT06371417Phase 1Recruiting

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

NCT06249438Phase 1Recruiting

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Showing all 3 trials

Research Network

Activity Timeline